K
Klaus Pantel
Researcher at University of Hamburg
Publications - 566
Citations - 36666
Klaus Pantel is an academic researcher from University of Hamburg. The author has contributed to research in topics: Circulating tumor cell & Cancer. The author has an hindex of 90, co-authored 486 publications receiving 29848 citations.
Papers
More filters
Journal ArticleDOI
Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions
TL;DR: A recent review as discussed by the authors describes recent advances in different cell-free DNA (cfDNA) approaches for early detection and monitoring of cervical cancer and its precursor lesions, and describes the clinical relevance of CFD in cervical cancer.
Patent
Immortalized epithelial tumor cell
TL;DR: In this paper, the use of the epithelial tumor cells and/or antibodies of the invention for the preparation of tumor vaccines and medicaments for the prophylaxis or treatment of cancer and the metastasis of cancer.
Journal ArticleDOI
Clinical Relevance of Micrometastatic Disease in Patients with Solid Tumors
Volkmar Müller,Klaus Pantel +1 more
TL;DR: The available data indicate that micrometastatic cells represent a selected population of cancer cells that express a considerable degree of heterogeneity with regard to chromosomal aberrations and phenotypic properties, which may help to design new strategies to detect and eliminate minimal residual cancer.
Journal ArticleDOI
Loss of 4q21.23-22.1 is a prognostic marker for disease free and overall survival in non-small cell lung cancer.
Faik G. Uzunoglu,Ebba Dethlefsen,Annkathrin Hanssen,Michaela Wrage,Lena Deutsch,Katharina Harms-Effenberger,Yogesh K. Vashist,Matthias Reeh,Guido Sauter,Ronald Simon,Maximillian Bockhorn,Klaus Pantel,Jakob R. Izbicki,Harriet Wikman +13 more
TL;DR: The data indicate that loss at 4q21.23-22.1 in NSCLC is of prognostic relevance inNSCLC patients and thus, includes potential new tumor suppressor genes with clinical relevance.
Journal ArticleDOI
Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments
Iga K Mieczkowska,Garyfallia Pantelaiou-Prokaki,Garyfallia Pantelaiou-Prokaki,Evangelos Prokakis,Geske Schmidt,Lukas C Müller-Kirschbaum,Marcel Werner,Madhobi Sen,Taras Velychko,Katharina Jannasch,Christian Dullin,Christian Dullin,Joanna Napp,Joanna Napp,Klaus Pantel,Harriet Wikman,Maria Wiese,Christof M. Kramm,Frauke Alves,Frauke Alves,Florian Wegwitz +20 more
TL;DR: In this article, the same cells showed a pronounced reduction of polycomb repressive complex 2 (PRC2) activity via downregulation of its subunits Ezh2, Suz12, Rbbp7 and Mtf2.